

# **ENDOMETRIAL ABLATION**

Review

*Submitted for Fulfillment of Master Degree in  
Obstetrics and Gynecology*

By

**Sherin Hassan Hanafy Mohamed**

(M.B.B.Ch)

Faculty of Medicine

Cairo University

*Under the Supervision of*

**Dr. Hany Hassan Mostafa**

Professor in Obstetrics and Gynecology

Faculty of Medicine, Cairo University

**Dr. Hassan Omar Ghareeb**

Assistant Professor in Obstetrics and Gynecology

Faculty of Medicine, Cairo University

**Dr. Ahmed Mahmoud Sayed**

Lecturer in Obstetrics and Gynecology

Faculty of Medicine, Cairo University

**Faculty of Medicine**

**Cairo University**

**2007**

# محو بطانة الرحم

رسالة مقدمة من

الطبيبة/ شيرين حسن حنفى محمد  
(بكالوريوس الطب والجراحة – جامعة القاهرة)  
توطئة للحصول على درجة الماجستير

فى

## أمراض النساء والتوليد

تحت إشراف

الأستاذ الدكتور/ هانى حسن مصطفى  
أستاذ أمراض النساء والتوليد  
كلية الطب – جامعة القاهرة

الدكتور/ حسن عمر غريب  
أستاذ مساعد أمراض النساء والتوليد  
كلية الطب – جامعة القاهرة

الدكتور/ أحمد محمود سيد  
مدرس أمراض النساء والتوليد  
كلية الطب – جامعة القاهرة

كلية الطب – جامعة القاهرة

2007

بسم الله الرحمن الرحيم

﴿قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا  
إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ﴾

صدق الله العظيم

سورة البقرة – آية 32

## *Acknowledgments*

*First of all thanks to **God**, the most beneficent and merciful.*

*I would like to express my deepest appreciation and profound gratitude to Professor Dr. **Hany Hassan Mostafa**, for his highly valuable supervision and kind instructions that were the cornerstone without which this work could not have been built.*

*I would like to express my sincere gratitude and deep thanks to Assistant Professor Dr. **Hassan Omar Ghareeb**, for his generous advice, valuable remarks and criticism.*

*I am greatly indebted to Dr. **Ahmed Mahmoud Sayed**, for his precious guidance and unlimited support that helped me complete this review in a timely fashion.*

*Finally, I extend my thanks to include all members of my **parents** my **husband** and my **kids**, to whom I dedicate this work for their love and support which made every difficulty I met surmountable.*

## **LIST OF ABBREVIATIONS**

CI	Confidence interval
CO <sub>2</sub>	Carbon dioxide
CPA	Cyproterone acetate
DUB	Dysfunctional uterine bleeding
DVT	Deep venous thrombosis
EA	Endometrial ablation
ELA	Endometrial laser ablation
ELITT	Laser interstitial hyperthermy endometrial laser intrauterine thermotherapy
FDA	Food and Drug Administration (United States)
GHz	Gigahertz
GnRH	Gonadotropin-releasing hormone
HCT	Hematocrit
HGB	Hemoglobin
HMB	Heavy menstrual bleeding
HPFB	Health Products and Food Branch (Canada)
HRT	Hormone replacement therapy
HTA	Hydro ThermAblator®
HTAC	Health Technology Advisory Committee (United States)
ITP	Idiopathic thrombocytopenic purpura
IUD	Intrauterine device
kHz	Kilohertz
kPa	Kilopascal
LAVH	Laparoscopic assisted vaginal hysterectomy
lb	libra (pound)
MBL	Menstrual blood loss
MEA	Microwave Endometrial Ablation™
Nd:YAG	Neodymium: yttrium-aluminum-garnet laser
NHSCRD	NHS Centre for Reviews and Dissemination (United Kingdom)
NSAIDs	Nonsteroidal antiinflammatory drugs
OR	Odds ratio
PMS	Premenstrual syndrome
psi	Pascal square per inch
QALY	Quality-adjusted life-year
®	Registered trademark
RBC	Red blood cell
TCRE	Transcervical resection of the endometrium
TM	Trademark
W	Watt

## LIST OF FIGURES

<i>Figure</i>	<i>Title</i>	<i>Page</i>
1	Work-up of reproductive age women with DUB	<b>11</b>
2	Work-up of women with postmenopausal bleeding or chronic anovulation.	<b>20</b>
3	Uterine artery embolization	34
4	Operative hysteroscope with wire loop and roller ball electrode.	84
5	Microsulis MEA System	103
6	Warmed solution circulating inside the balloon results in thermal injury to the endometrial tissue.	111
7	ThermaChoice uterine balloon therapy system	112
8	Hydrothermal ablation sterile procedure kit.	122
9	Hydro Thermablator	122
10	Her Option uterine Cryoablation therapy system	133
11	Novasure Impedence Controller endometrial ablation system	137

# LIST OF TABLES

<i>Table</i>	<i>Title</i>	<i>Page</i>
1	Evidence of involvement of prostaglandins in menstruation	7
2	Differential diagnosis of abnormal uterine bleeding	10
3	Possible endometrial factors involved in menorrhagia in women with DUB	14
4	Summary of levels of evidence of investigations for menorrhagia.	22
5	Medical management of abnormal uterine bleeding.	24
6	Summary of evidence for management of excessive menstrual bleeding.	28
7	Methods of endometrial destruction	41
8	Indications of endometrial ablation	44
9 A	Results of uncontrolled clinical studies of laser endometrial ablation: Efficacy results	67
9B	Results of uncontrolled clinical studies of laser endometrial ablation: Safety results	68
10A	Results of uncontrolled clinical studies of transcervical resection of the endometrial ablation: Efficacy results	78
10B	Results of uncontrolled clinical studies of transcervical resection of the endometrial ablation: Safety results	80
11	Practical problems and their solutions during endometrial ablation	83
12A	Results of uncontrolled clinical studies of rollerball endometrial ablation: Efficacy results.	88
12B	Results of uncontrolled clinical studies of rollerball endometrial ablation: Safety results.	90
13	Advantages and disadvantages of radiofrequency endometrial ablation	101
14A	Results of uncontrolled clinical studies of microwave endometrial ablation (MEA): Efficacy results	108

<i>Table</i>	<i>Title</i>	<i>Page</i>
14B	Results of uncontrolled clinical studies of microwave endometrial ablation (MEA): Safety results.	109
15A	Results of uncontrolled clinical studies of thermal balloon endometrial ablation (ThermaChoice): Efficacy results.	115
15B	Results of uncontrolled clinical studies of thermal balloon endometrial ablation (ThermaChoice): Safety results.	116
16A	Results of a randomized, controlled trial of thermal balloon endometrial ablation (ThermaChoice) with and without endometrial thinning agents: Efficacy results.	117
16B	Results of a randomized, controlled trial of thermal balloon endometrial ablation (ThermaChoice) with and without endometrial thinning agents: Safety results.	117
17A	Results of uncontrolled clinical studies of hydrothermal endometrial ablation (HTA): Efficacy results.	125
17B	Results of uncontrolled clinical studies of hydrothermal endometrial ablation (HTA): Safety results.	126
18	Characteristics and results of economic evaluations of first-generation endometrial ablation techniques and hysterectomy.	145
19	Results of prospective, comparative economic evaluation of the first-generation endometrial ablation techniques and hysterectomy.	153
20	Results of retrospective, comparative economic evaluations of the first-generation endometrial ablation techniques and hysterectomy.	154



# CONTENTS

	<i>Page</i>
INTRODUCTION.....	1
REVIEW OF LITERATURE:	
Chapter I:	
Physiological Background.....	4
Chapter II:	
Endometrial Ablation Techniques In The Treatment Of Dysfunctional Uterine Bleeding.....	38
Chapter III:	
Economic Aspects Of Endometrial Ablation In The Treatment Of Dysfunctional Uterine Bleeding.....	142
SUMMARY.....	163
REFERERNCES.....	169
ARABIC SUMMARY.....	

## **INTRODUCTION**

Dysfunctional uterine bleeding is one of the most common reasons for referral to a gynecologist. It is the main reason for consultation in more than 50% of women who undergo hysterectomy (*NHSCRD, 1995*).

In spite of good clinical acumen and appropriate investigations, it is possible that women may be subjected to many unnecessary gynecological procedures. A young woman with submucous myoma may be hysterectomized, a pubertal virgin with idiopathic thrombocytopenic purpura (ITP), may undergo hysteroscopy and curettage, and a young hypothyroid woman may be prescribed large amounts of hormones and probably undergo curettage by every different gynecologist she visits. The gynecologists must establish strategies that ensure that pertinent diagnosis is an integral part of their clinical armamentarium. In the words of Hippocrates, "You can not treat a patient unless you have arrived at a diagnosis ". The ability to diagnose menorrhagia, which is an extremely common condition, is vital and the gynecologist should apply common sense to the science of diagnosis. Appropriate treatment also requires patience on the part of the gynecologist. Fortunately, recent technical advances have produced a plethora of alternatives to hysterectomy providing the perplexed practitioner with a guide to plotting a course through this ever increasing maze of options (*Sheth and Sutton, 1999*).

Hysterectomy has, for a long time, been the definitive treatment for dysfunctional uterine bleeding (*Lethaby and Hickey, 2001*). It guarantees the cessation of menstrual blood loss, and most women are extremely

satisfied after the operation. However, it is a major surgical procedure with inherent risks and the potential for complications.

Although mortality from hysterectomy for benign disorders is low, short term morbidity may be as high as 42.8% (*Dicker et al., 1982*). There is also considerable concern with respect to the long term sequelae of hysterectomy, which may include premature onset of ovarian failure, psycho-sexual dysfunction, and urinary tract symptoms (*Magos, 1990*). In addition, the cost of the procedure and hospital stay are high.

Hysterectomy is more expensive than other treatment for DUB. But the use of vaginal route reduces the cost gap relative to endometrial ablation. (*Power et al., 1993*) proponents of LAVH have suggested that it's over all cost it would be less, in that it facilitates early discharge from the hospital and rapid return to reproductive employment. The costs of LAVH are twice those of abdominal hysterectomy. Trice those of vaginal hysterectomy and five times those of transcervical resection of the endometrium (TCRE) (*Nezhat et al., 1994*). However despite the higher operative cost, the total cost of treatment is less because of shorter hospital stay after LAVH (*Raju, 1994*).

Conservation of the uterus is increasingly being demanded; as nearly one half of all women with menorrhagia have no local pelvic pathology (*Fraser1992*). These patients are eminently suitable for endometrial ablation if they do not wish to preserve their fertility.

Recent advances in hysteroscopic technique now appear to offer an effective, less invasive, and certainly less costly approach to the management of dysfunctional uterine bleeding (*James et al., 1992*).

The first generation ablation techniques are assisted hysteroscopically, with direct, real-time visual monitoring of the uterine cavity, and are based on the use of laser electrosurgical techniques. . This surgical procedure permits preservation of the uterus and reduces uterine bleeding in most patients (*Goldrath et al., 1981*). They are designed to destroy the entire thickness of the endometrium .Although very effective, these techniques carry certain risks. Furthermore, they are often complex to perform and require an experienced surgeon. A second generation of endometrial ablation techniques is therefore being developed. These new procedures are technically simpler and carry fewer risks.

Since endometrial glandular tissue is present deep in the myometrium, ablation should therefore include endometrium and 2.5-3 mm of myometrium (*Coulter et al., 1991*). This means that surgery is best carried after endometrial suppression. Either danazol or gonadotrophin releasing hormone agonist may be used for endometrial suppression (*Sutton and Ewen, 1994*).

Furthermore, the latest surgical procedures offer a shorter convalescence and lead to fewer complications than abdominal hysterectomy (*Hidlebaugh, 2000; Lethaby et al., 2000d*). Many women prefer a less invasive surgical treatment, although the success of such a procedure is not always guaranteed (*Lethaby and Hickey, 2001*).

## **CHAPTER I**

### **Physiological Background**

#### **Definition of menstruation:**

The normal menstrual cycle is defined as having a mean interval of  $28 \pm 7$  days, with a mean duration of  $4 \pm 3$  days. The amount of blood loss average 30ml per cycle but may be as high as 80ml.

#### **Menstruation:**

Normal menstrual bleeding caused by postovulatory estrogen-progesterone withdrawal is stable and precisely regulated (*Speroff, Glass and Kase, 2005*). The normal menstrual cycle is so predictable that women come to expect a characteristic pattern of flow. Therefore, minor deviations in their expected use of sanitary napkins or tampons may cause women considerable concern. The usual duration of menstrual flow is 4 to 6 days, but many women may have a flow for as little as 2 days or as many as 7 days (*Speroff, Glass and Kase, 2005*). Normal menstruation also tends to be consistent in the amount of blood that is lost. The usual volume of menstrual blood loss is 30 ml; a menstrual flow greater than 80 ml is considered abnormal (*Speroff, Glass and Kase, 2005*).

The frequency and duration of menstrual flow are mostly stable during a woman's reproductive years, but they commonly vary at the beginning and end of the reproductive years (*Belsey and Pinol, 1997*).

By age 25, more than 40% of cycles are 25 to 28 days in length; between the ages of 25 and 35, more than 60% of cycles are 25 to 28 days in length (*Speroff, Glass, Kase . 2005*). The cycles begin to lengthen again when women enter their 40s, as perimenopause approaches.

Based on the normal experience, menstrual bleeding more often than every 24 days or less than every 35 days deserves evaluation (*Munster et al., 1992*). The flow that lasts 7 or more days also deserves evaluation. A flow that totals more than 80ml per month usually leads to anaemia and should be treated (*Higham et al. 1990*).

In general, however, an effort to quantitate menstrual blood flow beyond historical information is not necessary because evaluation and treatment are responses to a patient's own perceptions regarding duration, amount, and timing of her menstrual bleeding. Although the correlation between a patient's perceptions and actual menstrual blood loss is poor, an individual patient's anxiety and concern deserve consideration and evaluation (*Fraser et al., 1984*).

### **Mechanism of menstruation:**

The mechanisms underlying normal menstruation remain poorly understood but have been explained by three basic theories:

- a) Vascular control in the endometrial spiral arteries.
- b) Changes in local uterine haemostasis, and
- c) Regeneration of the endometrium (*Shaw, 1994*).

Prostaglandins are involved in the vascular control of the spiral arterioles and may have a modulatory role because withdrawal of progesterone will enhance prostaglandin synthesis. Platelet plugging is one of the major haemostatic mechanisms in the peripheral haemostasis, but can only be demonstrated in the spiral arterioles of the endometrium in the first twenty hours following the onset of menstrual bleeding (*Smith and Kelly 1987*).

Menstrual blood form clots in the first instance and then the fibrin is broken down by the proteolytic enzymes plasmin formed by the fibrinolytic system. The rapid formation and degeneration of fibrin plugs may play a role in the control of menstrual bleeding. The appearance of clots in the menstrual fluid implies an over coming of the fibrinolytic system of the uterus, and is often a pointer to menorrhagia (*Shaw, 1994*).

Prostaglandins have both vasoconstricting and vasodilating properties and playing a role in the control of endometrial bleeding. Prostaglandin synthetase, a group of enzymes, converts arachidonic acid to primary prostaglandin which leads to the production of thromboxane A<sub>2</sub> in platelets and prostacyclin in endothelial smooth muscle cells. Thromboxane A<sub>2</sub> acts as a powerful vasoconstrictor and platelet aggregator whilst prostacyclin has an opposing effect on hemostasis and act as a potent vasodilator and inhibitor of platelet aggregation. Thus a careful balance between the two is needed to achieve haemostasis in the endometrium. An imbalance towards prostacyclin would lead to bleeding disorders (*Shaw, 1994*).

Extensive research during recent years suggests that most excessive uterine bleeding is due to local endometrial or myometrial

---